Le Petit Livre du Cannabis Médical Nicolas Authier, Editions First, 2021, 149 pages Sommaire Petit livre Cannabis Médical - N Authier
Lire la suiteCannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International, 2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627 SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]
Lire la suiteModern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86 All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]
Lire la suiteThe current state and future perspectives of cannabinoids in cancer biology Paweł Śledziński, Joanna Zeyland, Ryszard Słomski & Agnieszka Nowak Cancer Medicine, 2018, 7, (3), 765–775. doi : 10.1002/cam4.1312 Abstract To date, cannabinoids have been allowed in the palliative medicine due to their analgesic and antiemetic effects, but increasing number of preclinical studies indicates their anticancer properties. Cannabinoids exhibit their action by a modulation of the signaling pathways crucial in the control of cell proliferation and survival. Many in vitro and in vivo experiments have shown that cannabinoids inhibit proliferation of cancer cells, stimulate autophagy and apoptosis, and have also a potential to inhibit angiogenesis [...]
Lire la suiteBibliographie CANNABINOÏDES et Traitement des Nausées et Vomissements Docteur Christian SUEUR, GRECC, 2e édition, janvier 2020. Le Cannabis comme anti-émétique : Les prescriptions médicales, chez les adultes (THC naturel ou synthétique - Nabilone) comme chez les enfants (delta 8-THC, Abrahamov et al, 1995), ont débutées dès 1975. L’efficacité a été prouvée dans de nombreux essais cliniques, et de nombreuses méta-analyses (8/9 pour le cannabis et 3/3 pour le Nabilone, Penta et al, 1981). Par contre les effets psychotropiques peuvent être mal supportés par de nombreux patients, et justifie l’arrêt, ou la diminution des doses. Les associations variables THC/CBD présente un intérêt probable. Aucun effet indésirable persistant ou fatal [...]
Lire la suiteBibliographie CANNABINOÏDES et Soins Palliatifs dans les pathologies cancéreuses Docteur Christian SUEUR, GRECC, janvier 2020. ("Work in Progress".... vos contributions seraient les bienvenues !) voir également : Bibliographie : Cannabinoides et traitement des nausées et vomissements
Lire la suiteThe cannabinoids : An overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection R. Mechoulam PhD, L Hanus PhD Pain Research Management, 2001, 6, (2), 67-73. Doi : 10.1155/2001/183057 The present paper describes the historical use of cannabis, starting with its use in Assyria and China. Recent advances in the understanding of the molecular basis of cannabis action are explained, including the identification of the cannabinoid receptors CB1 and CB2, as well as the isolation of endogenous cannabinoids from the brain and periphery. The use of delta9-tetrahydrocannabinol as an antivomiting and antinausea drug for cancer [...]
Lire la suiteOpportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 Doi : 10.1177/1758835919866362 Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review [...]
Lire la suiteCan Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect ? Jacob S. Aday, Emily K. Bloesch, & Christopher C. Davoli Journal of Cognitive Enhancement, August 2019 DOI: 10.1007/s41465-019-00151-6 Abstract Older adulthood can be characterized by various cognitive and affective changes. In general, older adults show declines in creativity and executive functioning. They also score lower in openness to experience, empathy, and many suffer from a paucity of meaningful experiences. Further, depression, pessimism, and suicide can be major concerns for this population. Although currently there are few interventions that can effectively address these changes, recent findings from psychedelic science suggest myriad parallels between the effects [...]
Lire la suiteSerotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease : A systematic review Simon Reiche, Leo Hermle, Stefan Gutwinskic Henrik Jungaberle, Peter Gasser, Tomislav Majić Progress in Neuropsychopharmacology & Biological Psychiatry, 2018, 81, 1–10 http://dx.doi.org/10.1016/j.pnpbp.2017.09.012 A B S T R A C T Anxiety and depression are some of the most common psychiatric symptoms of patients suffering with lifethreatening diseases, often associated with a low quality of life and a poor overall prognosis. 5-HT2A-receptor agonists (serotonergic hallucinogens, ‘psychedelics’) like lysergic acid diethylamide (LSD) and psilocybin were first investigated as therapeutic agents in the 1960s. Recently, after a long [...]
Lire la suite